CN104435123B - A kind of drug for treating rhinopathy - Google Patents

A kind of drug for treating rhinopathy Download PDF

Info

Publication number
CN104435123B
CN104435123B CN201410739462.5A CN201410739462A CN104435123B CN 104435123 B CN104435123 B CN 104435123B CN 201410739462 A CN201410739462 A CN 201410739462A CN 104435123 B CN104435123 B CN 104435123B
Authority
CN
China
Prior art keywords
parts
drug
pharmaceutical chemicals
bulk pharmaceutical
rhinitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410739462.5A
Other languages
Chinese (zh)
Other versions
CN104435123A (en
Inventor
朱本宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANLONG COUNTY DONGFANG WUGUANLING PRODUCTS FACTORY
Original Assignee
ANLONG COUNTY DONGFANG WUGUANLING PRODUCTS FACTORY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANLONG COUNTY DONGFANG WUGUANLING PRODUCTS FACTORY filed Critical ANLONG COUNTY DONGFANG WUGUANLING PRODUCTS FACTORY
Priority to CN201410739462.5A priority Critical patent/CN104435123B/en
Publication of CN104435123A publication Critical patent/CN104435123A/en
Application granted granted Critical
Publication of CN104435123B publication Critical patent/CN104435123B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/264—Aristolochia (Dutchman's pipe)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a kind of drugs for treating rhinopathy, by weight, including following bulk pharmaceutical chemicals：12-17 parts of Radix Salviae Miltiorrhizae, 8-13 parts of the seed of cowherb, 10-15 parts of Rhizoma Chuanxiong, 12-17 parts of Centipeda minima, 12-17 parts of the root of Dahurain angelica, 12-17 parts of the flower bud of lily magnolia, 8-13 parts of radix scutellariae, 8-13 parts of the achene of Siberian cocklebur, 1-5 parts of asarum, 1-3 parts of borneol.By above-mentioned each raw material medicaments in part by weight sampling, cleaning, dry sterilization, immersion, decoction, filtering, cooling, again sterilizing, thus obtaining the product.Drug provided by the present invention has the characteristics that rapid-action, good effect, Small side effects.Clinical totally 647 uses, average cure rate is 92.8%, and medication is convenient and efficient.

Description

A kind of drug for treating rhinopathy
Technical field
The invention belongs to the field of Chinese medicines, and in particular to a kind of drug for treating rhinopathy.
Background technology
Nose is the important portal and initiating terminal of human respiratory tract, and rhinopathy is an extremely wide common disease, multiple Disease.
The pathogenic factor of common rhinopathy includes：（1）Weather：When temperature change is larger, either quenching or shock heating easy So that schneiderian membrane is stimulated and is susceptible to suffer from acute or chronic rhinitis；（2）Ambient enviroment：When work or living environment are in drying, powder In the case that dirt or harmful substance pollute, it is easy to schneiderian membrane be made to be stimulated and damage；（3）Bad life habits：As often It picks the nose, pulls out vibrissa, cause nasal cavity skin injury and hair follicles damage and secondary infection；And easy damaged nasal septum venous blood pipe network, Lead to nosebleed；（4）Inappropriate medication：Such as nose drop vasoconstrictor, especially Naphazoline for a long time, Drug nose can be caused Inflammation makes the nasal obstruction symptom of patient be more difficult to release；（5）Being closed on organ lesion by nose is influenced：Amygdala is scorching, and pharyngitis etc. can Because lesion is spread, inflammation spreads and influences nose, causes rhinopathy；（6）Systemic factor：Such as anaemia, diabetes, rheumatism, It can make Abwehrkraft des Koepers reduction and nasal membrane blood circulation disorder and cause rhinopathy.
The pathogenic factors of common rhinopathy includes：（1）Inherent cause：There is allergy family history person to be susceptible to suffer from this disease, Huan Zhejia There are asthma, nettle rash or drug allergy history in front yard more；（2）Schneiderian membrane neurological susceptibility：The generation of neurological susceptibility is derived from the frequent of antigenic substance Stimulation, but its susceptible degree then regards mast cell in nasal mucosal tissue, the quantity of basophilic granulocyte and release chemical mediator Ability；（3）Antigenic substance and eating property allergen：The former refers to sucks nasal cavity by breathing, this allergoid is suspended in air more In, the latter refers to the allergenic substances for entering human body by alimentary canal and causing sniffle, acts on the mode of schneiderian membrane very Complexity, still not very clear so far, milk, eggs, fishes and shrimps, meat, fruit or even certain vegetables can all become allergen.
Currently, there are many drug for the treatment of rhinopathy in the market, it mostly can only symptomatic treatment, usually palliative, recurrence rate It is high and patient may be made to generate the dependence to drug.
Invention content
The purpose of the present invention is to provide the drugs of a kind of rapid-action, good effect, the treatment rhinopathy of Small side effects.
A kind of drug for treating rhinopathy of the present invention, by weight, including following bulk pharmaceutical chemicals：
12-17 parts of Radix Salviae Miltiorrhizae, 8-13 parts of the seed of cowherb, 10-15 parts of Rhizoma Chuanxiong, 12-17 parts of Centipeda minima, 12-17 parts of the root of Dahurain angelica are pungent It is 12-17 parts smooth, 8-13 parts of radix scutellariae, 8-13 parts of the achene of Siberian cocklebur, 1-5 parts of asarum, 1-3 parts of borneol.
Preferred weight part of above-mentioned each bulk pharmaceutical chemicals is：
15 parts of Radix Salviae Miltiorrhizae, 10 parts of the seed of cowherb, 12 parts of Rhizoma Chuanxiong, 15 parts of Centipeda minima, 15 parts of the root of Dahurain angelica, 15 parts of the flower bud of lily magnolia, radix scutellariae 10 Part, 10 parts of the achene of Siberian cocklebur, 3 parts of asarum, 1 part of borneol.
A kind of drug for treating rhinopathy of the present invention, wherein the drug is spray.
A kind of preparation method of drug for treating rhinopathy of the present invention, adopts conventional spray preparation method, includes the following steps：
（1）Bulk pharmaceutical chemicals are screened, are sampled by weight, are cleaned, removal impurity；
（2）Each bulk pharmaceutical chemicals are uniformly mixed, through microwave drying, sterilizing；
（3）After impregnating 30min-60min with 10-15 times of water for injection of bulk pharmaceutical chemicals total amount, 20min-30min is decocted, filter, It is cooling；
（4）Sterilizing, packing, are put in storage after quality inspection.
Compared with prior art, the present invention there is apparent advantageous effect, as can be known from the above technical solutions：The present invention selects red Ginseng, the seed of cowherb, Rhizoma Chuanxiong, Centipeda minima, the root of Dahurain angelica, the flower bud of lily magnolia, radix scutellariae, the achene of Siberian cocklebur, asarum and borneol be raw material, by each drug it Between synergistic effect so that plurality of active ingredients is reached nose by Cutaneous permeation mode in function in exciting human, can be rapid The nutrition needed for cell is supplemented, micro-ion lymph metabolism is improved, promotes nose blood circulation, nose cell is made to restore Activity.Drug ingedient has the function of clearing heat and detoxicating, antibacterial anti-inflammatory, can repair the cell corroded by bacterium, effective to reach Rhinopathy is eliminated, nasal dyspnea, the problems such as nasal respiration is obstructed are solved.Its rapid-action, good effect, recurrence rate is low, irritation is small, Toxic side effect is small, and medication is convenient and efficient.Clinical 647 uses, treatment nasal polyp, concha hypertrophy, rhinitis sicca, paranasal sinus Inflammation, frontal sinusitis, nasal obstruction, allergic rhinitis, atrophic rhinitis, acute and chronic rhinitis average cure rate be 92.8%.
Specific implementation mode
Carry out the advantageous effect of the present invention is further explained the drug below by way of test example.
Test example：The clinical observation of drug of the present invention
Clinical data：
All cases 647.Wherein, male 320, women 327, max age 70 years old, minimal ages 3 years old.
Diagnostic criteria：
《Doctor trained in Western medicine the standard of curative effect evaluation》
Therapy：
Drug of the present invention is sprayed into intranasal, 2-3 times daily, each 0.2-0.5ml, 10 are 1 course for the treatment of, the 1-3 course for the treatment of ?.
Criterion of therapeutical effect：
It cures：Main clinic symptoms disappear；
Effectively：Main clinic symptoms are alleviated；
In vain：Main clinic symptoms are not improved.
Treatment results：
101 Nasal Polyps Patients use drugs of the present invention, healing 99, effective 1, invalid 1, cure rate 98.0%, Total effective rate is 99.0%；
82 concha hypertrophy patients use drugs of the present invention, healing 79, effective 2, invalid 1, and cure rate is 96.3%, total effective rate 98.8%；
82 rhinitis sicca patients use drugs of the present invention, healing 78, effective 2, invalid 2, and cure rate is 95.1%, total effective rate 97.6%；
84 paranasal sinusitis patients use drugs of the present invention, healing 78, effective 4, invalid 2, and cure rate is 92.9%, total effective rate 97.6%；
41 frontal sinusitis patients use drugs of the present invention, healing 32, effective 6, invalid 3, cure rate 78.0%, Total effective rate 92.7%；
102 nasal obstruction patients' use drugs of the present invention, healing 97, effective 2, invalid 2, cure rate 95.1%, always Effective percentage is 97.1%；
93 Allergic Rhinitis use drugs of the present invention, healing 88, effective 3, invalid 2, and cure rate is 94.6%, total effective rate 97.8%；
36 atrophic rhinitis patients use drugs of the present invention, healing 32, effective 1, invalid 3, and cure rate is 88.9%, total effective rate 91.7%；
26 acute and chronic rhinitis patients use drugs of the present invention, healing 25, effective 1, invalid 0, and cure rate is 96.2%, total effective rate 100%；
All 647 rhinopathy patients, the average cure rate using drug therapy aforementioned disorders of the present invention is 92.8%, average Total effective rate is 96.9%.
Embodiment 1
A kind of drug for treating rhinopathy, includes the following steps：
（1）Bulk pharmaceutical chemicals are screened, weigh Radix Salviae Miltiorrhizae 12g, seed of cowherb 13g, Rhizoma Chuanxiong 10g, Centipeda minima 17g, root of Dahurain angelica 12g are pungent Smooth 17g, radix scutellariae 8g, achene of Siberian cocklebur 13g, asarum 1g, borneol 1g are cleaned, removal impurity；
（2）Each bulk pharmaceutical chemicals are uniformly mixed, through microwave drying, sterilizing；
（3）30min is impregnated with 10 times of waters for injection of bulk pharmaceutical chemicals total amount, decocts 20min, filtering, cooling；
（4）Sterilizing, packing, are put in storage after quality inspection.
Embodiment 2
A kind of drug for treating rhinopathy, includes the following steps：
（1）Bulk pharmaceutical chemicals are screened, Radix Salviae Miltiorrhizae 17g, seed of cowherb 8g, Rhizoma Chuanxiong 15g, Centipeda minima 12g, root of Dahurain angelica 17g, the flower bud of lily magnolia are weighed 12g, radix scutellariae 13g, achene of Siberian cocklebur 8g, asarum 5g, borneol 3g are cleaned, removal impurity；
（2）Each bulk pharmaceutical chemicals are uniformly mixed, through microwave drying, sterilizing；
（3）60min is impregnated with 15 times of waters for injection of bulk pharmaceutical chemicals, decocts 30min, filtering, cooling；
（4）Sterilizing, packing, are put in storage after quality inspection.
Embodiment 3
（1）Bulk pharmaceutical chemicals are screened, weigh Radix Salviae Miltiorrhizae 15g, seed of cowherb 10g, Rhizoma Chuanxiong 12g, Centipeda minima 15g, root of Dahurain angelica 15g are pungent Smooth 15g, radix scutellariae 10g, achene of Siberian cocklebur 10g, asarum 3g, borneol 1g are cleaned, removal impurity；
（2）Each bulk pharmaceutical chemicals are uniformly mixed, through microwave drying, sterilizing；
（3）45min is impregnated with 12 times of waters for injection of bulk pharmaceutical chemicals, decocts 25min, filtering, cooling；
（4）Sterilizing, packing, are put in storage after quality inspection.
The above described is only a preferred embodiment of the present invention, being not intended to limit the present invention in any form, appoint What is simply repaiied to any made by above example according to the technical essence of the invention without departing from technical solution of the present invention content Change, equivalent variations and modification, in the range of still falling within technical solution of the present invention.

Claims (2)

1. a kind for the treatment of nasal polyp, concha hypertrophy, rhinitis sicca, paranasal sinusitis, frontal sinusitis, atrophic rhinitis, acute and chronic nose Scorching drug is made of following bulk pharmaceutical chemicals by weight：12-17 parts of Radix Salviae Miltiorrhizae, 8-13 parts of the seed of cowherb, 10-15 parts of Rhizoma Chuanxiong, 12-17 parts of Centipeda minima, 12-17 parts of the root of Dahurain angelica, 12-17 parts of the flower bud of lily magnolia, 8-13 parts of radix scutellariae, 8-13 parts of the achene of Siberian cocklebur, 1-5 parts of asarum, ice 1-3 parts of piece；
The drug is spray；
The preparation method of the drug, includes the following steps：
（1）Bulk pharmaceutical chemicals are screened, are sampled by weight, are cleaned, removal impurity；
（2）Each bulk pharmaceutical chemicals are uniformly mixed, through microwave drying, sterilizing；
（3）After impregnating 30min-60min with 10-15 times of water for injection of bulk pharmaceutical chemicals total amount, 20min-30min is decocted, filters, is cold But；
（4）Sterilizing, packing, are put in storage after quality inspection.
2. a kind of as described in claim 1 treat nasal polyp, concha hypertrophy, rhinitis sicca, paranasal sinusitis, frontal sinusitis, wither The drug of contracting rhinitis, acute and chronic rhinitis, it is characterised in that：By weight, it is made of following bulk pharmaceutical chemicals：15 parts of Radix Salviae Miltiorrhizae, king 10 parts of row, 12 parts of Rhizoma Chuanxiong, 15 parts of Centipeda minima, 15 parts of the root of Dahurain angelica, 15 parts of the flower bud of lily magnolia, 10 parts of radix scutellariae, 10 parts of the achene of Siberian cocklebur, asarum 3 are not stayed Part, 1 part of borneol.
CN201410739462.5A 2014-12-08 2014-12-08 A kind of drug for treating rhinopathy Active CN104435123B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410739462.5A CN104435123B (en) 2014-12-08 2014-12-08 A kind of drug for treating rhinopathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410739462.5A CN104435123B (en) 2014-12-08 2014-12-08 A kind of drug for treating rhinopathy

Publications (2)

Publication Number Publication Date
CN104435123A CN104435123A (en) 2015-03-25
CN104435123B true CN104435123B (en) 2018-11-06

Family

ID=52882385

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410739462.5A Active CN104435123B (en) 2014-12-08 2014-12-08 A kind of drug for treating rhinopathy

Country Status (1)

Country Link
CN (1) CN104435123B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104771508B (en) * 2015-04-20 2016-01-06 山东师范大学 A kind of Chinese medicine preparation for the treatment of rhinitis and preparation method thereof
CN105853701A (en) * 2016-04-29 2016-08-17 刘涛 Traditional Chinese medicine composition for treating nasosinusitis
CN107496505A (en) * 2017-09-30 2017-12-22 廖会吉 It is a kind of to treat rhinitis, nasosinusitis, the medicine and preparation method thereof of nasal polyp enlargement
CN114306541A (en) * 2020-09-30 2022-04-12 王志敏 Natural pure Chinese herbal medicine rhinitis cream and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102091128A (en) * 2011-03-14 2011-06-15 山东省千佛山医院 Traditional Chinese medicine composition for treating allergic rhinitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101172595B1 (en) * 2010-05-28 2012-08-08 김형일 A composition comprising the extract of Physalis alkekengi var. francheti Masters Hort as an active ingredient for preventing and treating inflammatory disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102091128A (en) * 2011-03-14 2011-06-15 山东省千佛山医院 Traditional Chinese medicine composition for treating allergic rhinitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
辛夷屏风散治疗慢性鼻炎30例;郭立伍等;《中国乡村医药》;20001231;第7卷(第7期);第22-23页 *

Also Published As

Publication number Publication date
CN104435123A (en) 2015-03-25

Similar Documents

Publication Publication Date Title
CN104435123B (en) A kind of drug for treating rhinopathy
CN103690835B (en) Traditional Chinese medicine for treating infantile eczema and preparation method of traditional Chinese medicine
CN104415317A (en) Plaster
CN1969992B (en) Pharmaceutical composition for treating acne and application method thereof
CN107753631A (en) A kind of Rhinitis treating medicinal cream of antibacterial sterilization and preparation method thereof
CN106421486A (en) Veterinary traditional Chinese medicine composition with heat clearing and toxicity removing effects and preparation method thereof
CN105233219A (en) Traditional Chinese medicine composition for treating chronic rhinitis
CN104587035B (en) Medicine composition for treating oral ulcer and preparation method for medicine composition
CN101406583A (en) Externally applied Chinese medicine ointment for treating pyogenic skin infection caused by skin traumatism
CN104510815B (en) Prevent and treat the Chinese medicine preparation of pork pig dermatitis
CN104721384A (en) Convergence ointment
CN107029158A (en) A kind of compound Chinese herb external preparation for treating a rabbits mange
CN106389704A (en) Medicine oil for treating onychomycosis and preparing method thereof
CN105663688A (en) Traditional Chinese medicine fumigant for treating diabetic foot
CN103386105B (en) Traditional Chinese medicine granule for curing children cough on early and middle period
CN103285265B (en) An external application preparation of Chinese medicinal herbs for the treatment of Malassezia folliculitis
CN104189729A (en) Traditional Chinese medicine composition for treating foreign body pneumonia of animals and preparation method thereof
CN1264566C (en) Medicine for treating prostatosis
CN104491004A (en) Rhinallergosis rhinitis cream and preparation method thereof
CN113768837A (en) Traditional Chinese medicine toothpaste and preparation method thereof
CN103623155A (en) Traditional Chinese medicinal preparation with antisepsis and anti-inflammation effects
CN117257900A (en) Pharmaceutical composition for treating chronic upper respiratory syndrome of cats as well as preparation method and application thereof
CN103083516B (en) Traditional Chinese medicine fumigation lotion used for treating children rubella
CN112691169A (en) Medicine for treating rhinopathy
CN109999175A (en) It is a kind of for eliminating the compound formulation and preparation method thereof of dark sore abscess dermatitis infections acne ulcer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant